Cellomics Announces IBM Advanced Business Partner Status
Pittsburgh, PA – June 8th 2004. Cellomics, Inc. announced today that their relationship with IBM Healthcare & Life Sciences has been elevated to the status of IBM Advanced Business Partner.
“As an Advanced Partner, we have a commitment to work with IBM to create solutions for our customers. We feel that the combination of Cellomics technology with IBM’s global organization and class leading technology will offer great benefits toour customer base,” said Judy P. Masucci, Ph.D., Director of Marketing at Cellomics. Cellomics and IBM are working together to provide solutions for management of HCS data using a combination of Cellomics High Content Informatics (HCi™) software and IBM server hardware as a complete solution to customers utilizing High Content Screening (HCS) Tools and Technologies. “As an IBM Advanced Business Partner we have been able to leverage IBM’s expertise in hardware and software to design HCi ‘appliances’ that bring together Cellomics® Store (our HCS database) and our HCS Application Server middleware with IBM server, storage and backup hardware. We are now able to offer our global customer base a range of powerful, off-the-shelf, scalable solutions for cost effectively managing large volumes of HCS data,” stated Mark Collins, Ph.D., Senior Product Manager of High Content Informatics at Cellomics. Cellomics and IBM plan to work together to launch additional solutions for HCS customers, based around IBM products in the future.
About IBM The goal of IBM Healthcare and Life Sciences is to rapidly bring IT technology to customers and IBM Business Partners in the fields of pharmaceutical research, biotechnology, genomics, health and other life science industries. IBM is a proven leader in data integration, supercomputing, high performance storage, e-business and information technology services. Long-term projects at IBM Research Centers and the IBM Deep Computing Institute foster collaboration with life science companies—bringing domain expertise and innovative technologies to the development of life science solutions. IBM actively collaborates with companies like Cellomics whose domain knowledge, products and resources can help build valuable solutions for our mutual customers. For more information please go to www.ibm.com/solutions/lifesciences.
About Cellomics Cellomics, Inc is automating drug discovery through a unique, cell-based assay platform that addresses the needs of Drug Discovery and Systems Biology groups by offering complete systems for High Content Screening (HCS). The platform includes HCS instrumentation (both fixed end-point and kinetic systems), informatics, cellular image analysis software (BioApplications), fluorescent reagents, kits, cell lines, and multiparametric assays. When applied to early drug discovery, this platform is proving to reduce the 'idea-to-discovery' cycle time in drug discovery, while increasing the probability of the therapeutic success of leads as well as enhancing throughput in systems biology and basic research. Cellomics’ proprietary platforms, including the ArrayScan® and KineticScan® HCS Readers, along with the vHCS™ Discovery Toolbox software and BioApplications, are in use at multiple sites within all of the top fifteen pharmaceutical companies, as well as leading pharmaceutical and biotechnology companies and academic centers globally. For additional information, please visit www.cellomics.com.
For further information, contact:
Judy P. Masucci, Ph.D. Director of Marketing Cellomics, Inc. 100 Technology Drive Pittsburgh, PA 15219 412-770-2200 x 2353 412-770-2450 (fax)
Last Updated ( Monday, 08 November 2004 )
Upcoming Events
December 13, 2008 ASCB 2008 Please visit our booth at the 49th Annual Meeting of the American Society for Cell Biology ...
Home 
Cellomics Announces IBM Advanced Business Partner Status
top